AXSM Axsome Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why AXSM matters now
Axsome Therapeutics, Inc. (AXSM) is a US stock in Healthcare. The latest InvestLog snapshot shows $205.40 with -1.14% on the session and $10.57B in market capitalization; recent performance reads 1-month +10.51% and YTD +37.16%.
The latest financial table shown here is Q1 2026, with revenue of $191.2M, net income of $-64.5M, and EPS of $-1.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.6%.
The latest indexable market news headline is "Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $259.50; recent insider activity includes JEFFS ROGER filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
234.95
P/S
18.20
EV/EBITDA
-74.14
DCF Value
$-467.88
FCF Yield
-0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
-24.8%
Net Margin
-26.6%
ROE
-260.0%
ROA
-26.4%
ROIC
-50.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $191.2M | $-64.5M | $-1.26 |
| Q4 2025 | $196.0M | $-28.6M | $-0.56 |
| FY 2025 | $638.5M | $-183.2M | $-3.68 |
| Q3 2025 | $171.0M | $-47.2M | $-0.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$262.38
Target (Median)
$259.50
Target Range
$200.00 - $380.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.